Agenus(US:AGEN)2026-03-16 21:19Revenue and Financial Performance - Agenus recognized approximately $4.2 million in pre-commercial product revenue for the year ended December 31, 2025, from sales of BOT+BAL through early access pathways [462]. - Non-cash royalty revenue related to the sale of future royalties increased by $7.6 million to approximately $108.6 million for the year ended December 31, 2025, due to increased net sales of GSK's vaccines containing the QS-21 adjuvant [463]. - The accumulated deficit as of December 31, 2025, was $2.18 billion, indicating significant losses since inception [460]. - The company has raised approximately $2.05 billion through various financing methods since inception, including common and preferred stock sales and royalty monetization transactions [481]. - Future cash requirements are estimated at $687.0 million for ongoing clinical trials and regulatory efforts, with $628.0 million already expensed as R&D costs [488]. - Net cash used in operating activities was $77.2 million for the year ended December 31, 2025, a decrease from $158.3 million in 2024, highlighting the company's ongoing cash flow challenges [490]. - Cash and cash equivalents decreased to $3.0 million as of December 31, 2025, down from $40.4 million in 2024, indicating a need for additional capital to support operations [484]. Research and Development - Research and development expenses decreased by 49% to $79.3 million for the year ended December 31, 2025, from $155.5 million for the year ended December 31, 2024 [464]. - Research and development (R&D) expenses totaled $79.3 million for the year ended December 31, 2025, a decrease from $155.5 million in 2024, with significant costs attributed to antibody programs and other R&D initiatives [472]. - The lead clinical program, botensilimab (BOT), received Fast Track designation from the FDA for treating patients with specific types of metastatic colorectal cancer [444]. - Agenus has collaborations with several companies, including Bristol-Myers Squibb and Merck, resulting in over a dozen antibody pre-clinical or clinical development programs [445]. - The company is focused on developing its saponin-based vaccine adjuvant platform, particularly the next-generation cultured plant cell QS-21 [455]. Expenses and Losses - General and administrative (G&A) expenses decreased by 24% to $54.4 million for the year ended December 31, 2025, down from $71.9 million in 2024, primarily due to a $9.1 million decrease in personnel-related expenses [466]. - Non-operating expenses increased by $8.1 million, resulting in a net expense of $2.2 million for the year ended December 31, 2025, compared to income of $5.8 million in 2024, mainly due to a $3.5 million loss on the deconsolidation of a foreign subsidiary [467]. - The company has incurred significant losses and is likely to continue doing so until it becomes a commercial entity generating profits [460]. - The accumulated deficit reached $2.18 billion as of December 31, 2025, with expectations of continued significant losses in the coming years as the company advances its technologies and product candidates [481]. Debt and Liabilities - Long-term debt amounts to $36.764 billion, with no payments due in the 1-3 years, 3-5 years, or beyond 5 years [492]. - Operating leases total $16.897 billion, with $2.396 billion due within 1 year, $4.897 billion in 1-3 years, $4.505 billion in 3-5 years, and $5.099 billion beyond 5 years [492]. - Finance leases are recorded at $127 million, with $110 million due within 1 year and $17 million in 1-3 years [492]. Currency and Interest Rate Exposure - Approximately 4.7% of cash used in operations for the year ended December 31, 2025, was from foreign subsidiaries, indicating exposure to foreign currency exchange rate fluctuations [501]. - The company does not currently employ specific strategies to manage foreign currency exchange rate risks, such as derivatives or hedging [501]. - The investment policy aims to preserve principal, maintain liquidity, and maximize yields, prohibiting investments in structured vehicles and asset-backed commercial paper [503]. - The company is exposed to fluctuations in interest rates as it seeks debt financing and invests excess cash [502]. - Non-cash interest expense related to royalty financing transactions is recorded based on estimated royalty payments, which may vary due to several factors [497]. - The company periodically assesses expected royalty payments using historical results and market forecasts, adjusting amortization of liabilities as necessary [498]. Other Significant Events - Incyte has terminated the OX40 program and intends to terminate the entire collaboration agreement by February 2026, reverting rights back to Agenus [446]. - The gain from the deconsolidation of MiNK Therapeutics, Inc. was $100.9 million for the year ended December 31, 2025, reflecting the loss of control in Q3 2025 [468]. - Interest expense decreased to $55.3 million for the year ended December 31, 2025, from $117.6 million in 2024, mainly due to reduced non-cash interest related to the Royalty Purchase Agreement [470].